Streamlining chemotherapy prior authorizations: Leveraging resources to cut delays and boost revenue.

Abstract

573 Background: Prior authorizations (PAs) for systemic cancer treatments are a barrier to timely quality cancer care delivery. The high administrative burden to complete peer to peer’s (P2P) and appeals leads to care delays and revenue losses. At our tertiary academic cancer center, in partnership with our cancer registry and Epic teams, we shifted the clerical work required for PAs from clinicians to certified tumor registrars (CTRs) to increase authorization efficiency and decrease financial losses from denials. Methods: Clinicians place the treatment plan order which goes to the CTR work queue. We leveraged the Epic staging smart form to consolidate and auto-populate common elements needed for PA. The CTRs then complete and validate the form prior to the authorization specialists obtaining the PA. We compared the pre (1/2022-9/2022) and post-implementation (11/2022-5/2023) periods on our primary outcomes: average monthly number of PAs pending review (including P2P, appeals and authorizations requiring clarifying clinical documentation) and average time spent on PAs by the authorization specialists. We compared the same post implementation period to the same time the year before on the financial loss from denied PAs. Analyses were conducted using Welch's t-test. Results: There was an 11% reduction in the average monthly number of PAs pending review (350 vs 313; p=0.27) from pre to post implementation. There was an average improvement of 6 hours spent obtaining a final approval/per authorization (100 vs 106 hours; p=0.64) from pre to post implementation. In addition, there was a trend toward improvement in financial losses from PA denials from Dec 2022 to March 2023 and a cost savings of ~ 7 million dollars from the same time period pre-intervention; p=0.01 (Table). Conclusions: By leveraging the EHR and optimizing existing non-clinical staff workflows, we demonstrated a sustained decrease in the number of ambulatory PAs pending review, time spent on the PAs and significantly decreased financial losses from denials. Future work will include treatment and disease specific optimizations and evaluating the impact on clinician well-being.[Table: see text]